6533b854fe1ef96bd12af686
RESEARCH PRODUCT
Remnant vital tissue following locoregional therapy for hepatocellular carcinoma: another player in the game
Angel RubínAngel RubínMarina BerenguerMarina BerenguerMarina Berenguersubject
OncologyTarget lesionTransplantationmedicine.medical_specialtyTumor sizeTumor biologybusiness.industrymedicine.medical_treatmentEconomic shortageImmunosuppressionLiver transplantationmedicine.disease03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisHepatocellular carcinomaInternal medicinemedicine030211 gastroenterology & hepatologybusinessdescription
The applicability of liver transplantation (LT) as a curative option for patients with hepatocellular carcinoma (HCC) is limited by organ shortage. In addition to tumor size and number, other variables, particularly those that are surrogates of tumor biology should be incorporated into the allocation policies to improve the estimation of post-LT benefit. In this issue of Transplant International, Manzia et al. analyze the role of remnant vital tissue (RVT) of the target lesion after locoregional therapies (LRT) in predicting post-LT HCC recurrence This article is protected by copyright. All rights reserved.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-08-13 | Transplant International |